首页 | 本学科首页   官方微博 | 高级检索  
     

KIT-negative gastrointestinal stromal tumors with a long term follow-up: A new subgroup does exist
引用本文:Kontogianni-Katsarou K,Lariou C,Tsompanaki E,Vourlakou C,Kairi-Vassilatou E,Mastoris C,Pantazi G,Kondi-Pafiti A. KIT-negative gastrointestinal stromal tumors with a long term follow-up: A new subgroup does exist[J]. World journal of gastroenterology : WJG, 2007, 13(7): 1098-1102. DOI: 10.3748/wjg.v13.i7.1098
作者姓名:Kontogianni-Katsarou K  Lariou C  Tsompanaki E  Vourlakou C  Kairi-Vassilatou E  Mastoris C  Pantazi G  Kondi-Pafiti A
作者单位:Katerina Kontogianni-Katsarou(Department of Pathology,Athens Medical School,Areteion University Hospital,76,Vas.Sophias Ave.,Athens 11528,Greece) ;Constantina Lariou(Department of Pathology,Evaggelismos General Hospital,Ipsiladou 45-47,Athens 10676,Greece) ;Eugenia Tsompanaki(Department of Statistics,School of Economics and Business,Athens University,Patision 76,Athens 10434,Greece) ;Christina Vourlakou(Department of Pathology,Evaggelismos General Hospital,Ipsiladou 45-47,Athens 10676,Greece) ;Evi Kairi-Vassilatou(Department of Pathology,Athens Medical School,Areteion University Hospital,76,Vas.Sophias Ave.,Athens 11528,Greece) ;Costas Mastoris(Department of Pathology,Evaggelismos General Hospital,Ipsiladou 45-47,Athens 10676,Greece) ;Georgia Pantazi(Department of Pathology,Evaggelismos General Hospital,Ipsiladou 45-47,Athens 10676,Greece) ;Agatha Kondi-Pafiti(Department of Pathology,Athens Medical School,Areteion University Hospital,76,Vas.Sophias Ave.,Athens 11528,Greece) ;
基金项目:Supported by Hellenic State Scholarship Foundation,Department of Science Promotion,No.19366/2005
摘    要:

关 键 词:胃肠基质肿瘤  基因突变  免疫组织化学  治疗
收稿时间:2006-10-27

KIT-negative gastrointestinal stromal tumors with a long term follow-up: a new subgroup does exist
Kontogianni-Katsarou Katerina,Lariou Constantina,Tsompanaki Eugenia,Vourlakou Christina,Kairi-Vassilatou Evi,Mastoris Costas,Pantazi Georgia,Kondi-Pafiti Agatha. KIT-negative gastrointestinal stromal tumors with a long term follow-up: a new subgroup does exist[J]. World journal of gastroenterology : WJG, 2007, 13(7): 1098-1102. DOI: 10.3748/wjg.v13.i7.1098
Authors:Kontogianni-Katsarou Katerina  Lariou Constantina  Tsompanaki Eugenia  Vourlakou Christina  Kairi-Vassilatou Evi  Mastoris Costas  Pantazi Georgia  Kondi-Pafiti Agatha
Affiliation:1. Department of Pathology,Athens Medical School,Areteion University Hospital,76,Vas.Sophias Ave.,Athens 11528,Greece
2. Department of Pathology,Evaggelismos General Hospital,Ipsiladou 45-47,Athens 10676,Greece
3. Department of Statistics,School of Economics and Business,Athens University,Patision 76,Athens 10434,Greece
Abstract:AIMTo investigate the incidence of KIT immunoho-stochemical staining in(GI)stromal tumors(GISTs),and to analyze the clinical manifestations of the tumors and prognostic indicators.METHODSWe retrospectively analyzed 50 cases of Previously diagnosed GISTs.Tissue samples were assessed with KIT(CD117 antigen),CD34,SMA,desmin,S-100,NSE,PCNA,Ki-67,and BCL-2 for immunohistochemical study and pathological characteristics were analyzed for prognostic factors.RESULTSFifteen tumors(30%)were negative in KIT staining.A significant association was observed between gender(male patients14/15)and KIT-negative staining P = 0.003).The patients's mean age was 56.6 years.Tumors developed in stomach(n = 8),small intestine (n = 5),large intestine(n = 1)and oesophagus(n = 1).The mean tumor size was 5.72 cm.The mitotic count ranged from 0-29/50 HPF(mean3.4)and 73% of tumors showed no necrosis.The majority of the tumors(67%)had dual or epithelioid differentiation.Tumors were classified as very low or low risk(n = 7),intermediate risk(n = 5),and high risk(n = 3)groups.Twelve(80%)patients were alive without evidence of residual tumor for an average period of 40.25 mo(12-82 mo);three patients developed metastatic disease to the liver and eventually died within 2-12 mo(median survival8.6 mo).CONCLUSIONA small subgroup of GISTs fulfils the clinical and morphological criteria of these tumors,and lacks KIT expression.These tumors predominantly developed in the stomach,being dual or epithelioid in morphology,which are classified as low risk tumors and presented a better survival status than KIT-positive tumors.The ability to diagnose GISTs still depends on immunohistochemical staining but the research should extend in gene mutations.
Keywords:Gastrointestinal stromal tumors  CD 117 antigen  Immunohistochemistry  Survival
本文献已被 维普 万方数据 PubMed 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号